| 241/543 | US=10-A / Cirurgia Carvalho LEMR, Endo RM, Mariano Jr OP, Goldchmit M, Nakagawa A, Vadas MFG, Barcellos RB, Ejzembaum F. Estrabismo. In: Coelho JCU. Manual de clínica cirúrgica: cirurgia geral e especialidades. São Paulo: Atheneu, 2009. p. 2578-90. ISBN 85-388-009-5. ESTRABISMO. TRATAMENTO; ESOTROPIA; EXOTROPIA; PARALISIA OCULAR; DIVERGENCIA VERTICAL DISSOCIADA; DOENCA DE GRAVES; SINDROME DE BROWN; FIBROSE GENERALIZADA DE BROWN; SINDROME DE MOEBIUS; SINDROME DE DUANE |
| 242/543 | US=14 / Dermatologia Bos JD, Luiten RM. Skin immune system. In: Ulrich ESC, Euvrard S, Proby C, Bavinck JNB, Geissler EK. Skin cancer after organ transplantation. New York: Springer, 2009. p. 45-62. (Cancer Treatment and Reseach) ISBN 978-0-387-78573-8. PELE; SISTEMA IMUNOLOGICO; PELE. FUNCOES; CANCER; VIRUS ONCOGENICOS |
| 243/543 | US=16 / Nutrição Espíndola RM, Sardinha LMV, Galante AP. Avaliação nutricional em diferentes situações: crianças de zero a dez anos. In: Rossi L, Caruso L, Galante Ap. Avaliação nutricional: novas perspectivas. São Paulo: Roca, 2009. p. 163-225. ISBN 85-7241-762-4. ANTROPOMETRIA; DADOS ANTROPOMETRICOS; PESO; ESTATURA; DOBRAS CUTANEAS; PERIMETRO BRAQUIAL; PERIMETRO CEFALICO; PERIMETRO TORACICO; INDICADORES ANTROPOMETRICOS; INDICE DE MASSA CORPORAL; ESCORE-Z; PERCENTIL; PERCENTUAL DE ADEQUACAO; ANALISE DE DADOS ANTROPOMETRICOS |
| 244/543 | US=16 / Nutrição Espíndola RM, Galante AP. Avaliação nutricional em diferentes situações: adolescentes. In: Rossi L, Caruso L, Galante Ap. Avaliação nutricional: novas perspectivas. São Paulo: Roca, 2009. p. 226-46. ISBN 85-7241-762-4. ANTROPOMETRIA; DADOS ANTROPOMETRICOS; PESO; ESTATURA; DOBRAS CUTANEAS; PERIMETRO BRAQUIAL; PERIMETRO ABDOMINAL; INDICADORES ANTROPOMETRICOS; MATURACAO SEXUAL |
| 245/543 | US=22 / Urologia Bukowski RM, Figlin RA, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma: overview. In: ___. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 1-12. ISBN 978-1-58829-737-2. CARCINOMA DE CELULAS RENAIS; VHL GENE; PROTEINA VHL; VEGF; PDGF; TERAPIAS RCC |
| 246/543 | US=22 / Urologia Dhanani N, Vocke C, Bratslavsky G, Linehan WM. Molecular genetics in inherited renal cell carcinoma: identification of targets in the hereditary syndromes. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 13-33. ISBN 978-1-58829-737-2. NEOPLASIAS DE RIM; HIPPLE CON-LINDAU; BHD; BIRT-HOGG-DUBE; FUMARATO HIDRATASE |
| 247/543 | US=22 / Urologia Zhou M. Molecular targets in renal tumors: pathologic assessment. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 35-48. ISBN 978-1-58829-737-2. CARCINOMA DE CELULAS RENAIS; NEOPLASIA RENAL PATOLOGIA; CITOGENETICA; PROGNOSTICO |
| 248/543 | US=22 / Urologia Hutson TE, Thakkar S, Cohen P, Borden EC. Interferons and interleukin-2: molecular basis of activity and therapeutic results. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 49-78. ISBN 978-1-58829-737-2. INTERFERON; INTERLEUCINA; IFN-X2, IL-2; INIBICAO DA ANGIOGENESE; EFEITOS CLINICOS DA IL-2 E IFN |
| 249/543 | US=22 / Urologia Junior Kaelin WG, Geoge DJ. The molecular biology of kidney cancer and its clinical translation into treatment strategies. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 79-97. ISBN 978-1-58829-737-2. VON HIPPEL-LINDAU; HIPOXIA; ANGIOGENESE; HIF; VEGF; KDR; MTOR |
| 250/543 | US=22 / Urologia Rathmell WK, Rini BI. VEGF: biologic aspects and clinical approaches. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 99-118. ISBN 978-1-58829-737-2. |
| 251/543 | US=22 / Urologia Lam JS, Figlin RA, Belldegrum AS,. VEGF: and PDGF receptors: biologic relevance and clinical approaches to inhibition. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 119-49. ISBN 978-1-58829-737-2. DERIVADO DE PLAQUETAS FACTOR DE CRESCIMENTO; RECEPTORES; TRANSDUCAO DE SINAL; TIROSINA-QUINASE; FACTOR DE CRESCIMENTO ENDOTELIAL VASCULAR |
| 252/543 | US=22 / Urologia Motzer RJ. Sunitinib and axitinib in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 151-65. ISBN 978-1-58829-737-2. SUNITINIB; SU11248; AXITINIBE; CARCINOMA DE CELULAS RENAIS; SUTENT; AG-013736 |
| 253/543 | US=22 / Urologia George S, Bukowski RM. Sorafenib in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 167-87. ISBN 978-1-58829-737-2. CARCINOMA DE CELULAS RENAIS; SORAFENIB; INIBIDOR DE TIROSINA CINASE; VEGF; TERAPIA ANTIANGIOGENICA |
| 254/543 | US=22 / Urologia Rini BI. Additional tyrosine kinase inhibitors in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 189-93. ISBN 978-1-58829-737-2. INIBIDORES VEGF; TKI; PTK787; AZD2171; ZK222584; INIBIDOR DE TIROSINA CINASE; PAZOPANIB |
| 255/543 | US=22 / Urologia Ramakrishnan V, Bhaskar V, Fox M, Wilson K, Cheville JC, Finck BA. Integrin &*945;5&*946;1 as a noveltherapeutic target in renal cancer. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 195-209. ISBN 978-1-58829-737-2. INTEGRINAS NA ANGIOGENESE; TERAPIA ANTI-ANGIOGENICA; CANCER RENAL &*945;5&*946;1; VOLOCIXIMAB |
| 256/543 | US=22 / Urologia Shuch B, Belldegrun AS, Figlin RA. Carbonic anhydrase IX: biology and clinical approaches. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 211-29. ISBN 978-1-58829-737-2. CAIX; CCR CELULA CLARA; INTERLEUCINA-2 RESPOSTA; PROGNOSTICO; G250 |
| 257/543 | US=22 / Urologia Oosterwijk-Wakka JC, Boerman OC, Mulders PFA, Oosterwijk E. Monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma: biological and clinical studies. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 231-47. ISBN 978-1-58829-737-2. |
| 258/543 | US=22 / Urologia Reckamp KL, Figlin RA, Strieter RM. Chemokines in renal cell carcinoma: implications for tumor angiogenesis and metastasis. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 249-65. ISBN 978-1-58829-737-2. CARCINOMA DE CELULAS RENAIS; QUIMIOCINAS; ANGIOGENESE; POTENCIAL METASTATICO; TRATAMENTO |
| 259/543 | US=22 / Urologia Cho D, Mier JW, Atkins MB. PI3K/AKt/mTOR pathway: a growth and proliferation pathway. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 267-85. ISBN 978-1-58829-737-2. INIBIDORES PI3K; RCC; HIPERATIVACAO DO AKT/PI3K; ATIVIDADE AKT; TEMSIROLIMUS |
| 260/543 | US=22 / Urologia Jonasch E, Walker CL. EGFR and HER2: relevance in renal cell carcinoma. In: Bukowski RM, Figlin RA, Motzer RJ. Renal cell carcinoma: molecular targets and clinical applications. 2ªed. New York: Humana Press, 2009. p. 287-303. ISBN 978-1-58829-737-2. CARCINOMA DE CELULAS RENAIS; ERBB; TERAPIA-ALVO; RESISTENCIA; SINALIZACAO |